Learning Objectives

At the conclusion of this program, participants should be able to:

• Describe new and emerging strategies for improving patient outcomes in cancer patients using biologic therapies that target key processes in the growth of malignant cells.
• Compare and contrast the different types of monoclonal antibodies in terms of method of generation and safety and efficacy profile.
• Outline the role of the Epidermal Growth Factor Receptor in cancer development and prognosis.
• Review the results of recent clinical data in the treatment of metastatic colorectal cancer highlighting the results of key clinical trials using targeted therapies alone and in combination with traditional chemotherapeutic agents.